Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis

por Landau, H, Smith, M, Landry, C, Chou, J F, Devlin, S M, Hassoun, H, Bello, C, Giralt, S, Comenzo, R L
Publicado 2017

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis

por Merlini, G, Lousada, I, Ando, Y, Dispenzieri, A, Gertz, M A, Grogan, M, Maurer, M S, Sanchorawala, V, Wechalekar, A, Palladini, G, Comenzo, R L
Publicado 2016

Cancer-testis antigen expression and immunogenicity in AL amyloidosis

por Rosenzweig, M A, Landau, H, Seldin, D, O'Hara, C, Girnius, S, Hanson, N, Frosina, D, Sedrak, C, Arcila, M, Comenzo, R L, Giralt, S, Gnjatic, S, Jungbluth, A A, Koehne, G
Publicado 2012

P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES

por Gertz, M., Cohen, A., Comenzo, R., Kastritis, E., Landau, H., Libby, E., Liedtke, M., Sanchorawala, V., Schönland, S., Wechalekar, A., Ando, Y., Koh, Y., Zonder, J., Palladini, G., Nie, C., Karp, C., Jin, Y., Conrad, A., Kinney, G., Merlini, G.
Publicado 2023